Monthly Archives: May 2016

Generalized Anxiety Disorder (GAD)[/size] Generalized Anxiety Disorder (GAD) is characterized by six months or more of chronic, exaggerated worry and tension that is unfounded or much more severe than the normal anxiety most people experience. People with this disorder usually … Continue reading →

OCD (Obsessive compulsive disorder): People with obsessive-compulsive disorder (OCD) suffer intensely from recurrent unwanted thoughts (obsessions) or rituals (compulsions), which they feel they cannot control. Rituals, such as handwashing, counting, checking or cleaning, are often performed in hope of preventing … Continue reading →

Types of Bipolar Disorder There are several kinds of bipolar disorder. Each kind is defined by the length, frequency and pattern of episodes of mania and depression. Bipolar I Disorder Bipolar I disorder is characterized by one or more manic … Continue reading →

obert M. A. Hirschfeld, M.D. APA’s Practice Guideline for the Treatment of Patients With Bipolar Disorder, 2nd Edition, was published in April 2002 (1). Since that time, a number of controlled treatment studies on aspects of bipolar disorder have been … Continue reading →

Introduction The Growing Brain The Working Brain Brain Basics in Real Life Brain Research Glossary Brain Basics Welcome. Brain Basics provides information on how the brain works, how mental illnesses are disorders of the brain, and ongoing research that helps … Continue reading →

Overview Medications are used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as Psyhcotherapy. Psychotherapy alone may … Continue reading →

FDA has directed the manufacturers of all drug products approved for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) to develop patient Medication Guides to alert patients to possible cardiovascular risks and risks of adverse psychiatric symptoms associated with the medicines, … Continue reading →

Revisions to Product Labeling [These changes should be made to the box warning at the beginning of the package insert.] DRUG NAME Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in … Continue reading →